Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556931 · ClinicalTrials.gov registry record · Phase 2
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT02556931 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 117 participants.
The verdict
NCT02556931, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Tacrolimus
- RADIATION Total body irradiation
- DRUG Mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2015-12 |
| Est. Completion | 2021-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556931
The ClinicalTrials.gov registry entry for NCT02556931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02556931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02556931 about?
NCT02556931 is a clinical study titled "Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies". To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.
What is the current status of trial NCT02556931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2015-12. Estimated completion is 2021-04.
What interventions are being tested in trial NCT02556931?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Tacrolimus (DRUG), Total body irradiation (RADIATION), Mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT02556931?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.